Syndax Pharmaceuticals Inc (Nasdaq:SNDX), a United States-based clinical stage biopharmaceutical company, has named Daphne Karydas as its new chief financial officer, effective 13 July 2020, it was reported on Tuesday.
Karydas has over 20 years of financial experience in the biopharmaceutical industry. Prior to joining Syndax Pharmaceuticals, Karydas has held the position of senior vice president of Corporate Financial Planning and Analysis and Strategy at Allergan. She has also served as executive director and senior healthcare analyst at JP Morgan Asset Management, portfolio manager and senior healthcare analyst at The Boston Company Asset Management, vice president at Goldman Sachs Asset Management, a member of Goldman Sachs' healthcare investment banking team and project chemical engineer at Merck & Co.
Karydas is to replace Richard P Shea, who will be retiring from his role as the company's chief financial officer.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer